TD Cowen lowered the firm’s price target on Aspen Aerogels (ASPN) to $9 from $11 and keeps a Buy rating on the shares. Soft Q1 results and Q2 guidance turn “2025 into a transition year on further EV production weakness,” the analyst tells investors. However, the firm’s one to three year U.S. EV demand view is “still more constructive than consensus” and while it is reducing estimates it still likes the risk/reward post pullback, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPN:
- Aspen Aerogels price target lowered to $10 from $22 at B. Riley
- Aspen Aerogels price target lowered to $8 from $16 at Roth Capital
- Aspen Aerogels Faces Challenges Amid New Contract Win
- Aspen Aerogels Navigates Challenges in Earnings Call
- Aspen Aerogels downgraded to Perform at Oppenheimer on deteriorating demand